untitled
<OAI-PMH schemaLocation=http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd>
<responseDate>2018-01-15T18:31:30Z</responseDate>
<request identifier=oai:HAL:hal-01118441v1 verb=GetRecord metadataPrefix=oai_dc>http://api.archives-ouvertes.fr/oai/hal/</request>
<GetRecord>
<record>
<header>
<identifier>oai:HAL:hal-01118441v1</identifier>
<datestamp>2017-12-21</datestamp>
<setSpec>type:ART</setSpec>
<setSpec>subject:sdv</setSpec>
<setSpec>collection:UNIV-RENNES1</setSpec>
<setSpec>collection:IRSET</setSpec>
<setSpec>collection:UNIV-PARIS7</setSpec>
<setSpec>collection:UNIV-AG</setSpec>
<setSpec>collection:APHP</setSpec>
<setSpec>collection:IFR140</setSpec>
<setSpec>collection:HL</setSpec>
<setSpec>collection:U835</setSpec>
<setSpec>collection:IRSET-HIAEC</setSpec>
<setSpec>collection:BIOSIT</setSpec>
<setSpec>collection:UR1-UFR-SVE</setSpec>
<setSpec>collection:STATS-UR1</setSpec>
<setSpec>collection:USPC</setSpec>
<setSpec>collection:UR1-HAL</setSpec>
<setSpec>collection:EHESP</setSpec>
<setSpec>collection:UR1-SDV</setSpec>
<setSpec>collection:IRSET-2</setSpec>
<setSpec>collection:UNIV-ANGERS</setSpec>
</header>
<metadata><dc>
<publisher>HAL CCSD</publisher>
<title lang=es>Fungal endocarditis: current challenges.</title>
<creator>Tattevin, Pierre</creator>
<creator>Revest, Matthieu</creator>
<creator>Lefort, Agnès</creator>
<creator>Michelet, Christian</creator>
<creator>Lortholary, Olivier</creator>
<contributor>Fonction, structure et inactivation d'ARN bactériens ; Université de Rennes 1 (UR1) - Institut National de la Santé et de la Recherche Médicale (INSERM) - Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )</contributor>
<contributor>Service des maladies infectieuses et réanimation médicale ; Université de Rennes 1 (UR1) - Hôpital Pontchaillou</contributor>
<contributor>Service de médecine interne ; Hôpital Beaujon ; Assistance publique - Hôpitaux de Paris (AP-HP) - Université Paris Diderot - Paris 7 (UPD7) - Hôpital Beaujon - Assistance publique - Hôpitaux de Paris (AP-HP) - Université Paris Diderot - Paris 7 (UPD7) - Hôpital Beaujon</contributor>
<contributor>Institut de recherche, santé, environnement et travail [Rennes] (Irset) ; Université d'Angers (UA) - Université des Antilles et de la Guyane (UAG) - Université de Rennes 1 (UR1) - École des Hautes Études en Santé Publique [EHESP] (EHESP) - Institut National de la Santé et de la Recherche Médicale (INSERM) - Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )</contributor>
<contributor>CHU Pontchaillou [Rennes]</contributor>
<contributor>Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris</contributor>
<description>International audience</description>
<source>ISSN: 0924-8579</source>
<source>International Journal of Antimicrobial Agents</source>
<publisher>Elsevier</publisher>
<identifier>hal-01118441</identifier>
<identifier>https://hal-univ-rennes1.archives-ouvertes.fr/hal-01118441</identifier>
<source>https://hal-univ-rennes1.archives-ouvertes.fr/hal-01118441</source>
<source>International Journal of Antimicrobial Agents, Elsevier, 2014, 44 (4), pp.290-4. 〈10.1016/j.ijantimicag.2014.07.003〉</source>
<identifier>DOI : 10.1016/j.ijantimicag.2014.07.003</identifier>
<relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.ijantimicag.2014.07.003</relation>
<identifier>PUBMED : 25178919</identifier>
<relation>info:eu-repo/semantics/altIdentifier/pmid/25178919</relation>
<language>en</language>
<subject>[SDV] Life Sciences [q-bio]</subject>
<type>info:eu-repo/semantics/article</type>
<type>Journal articles</type>
<description lang=en>Whilst it used to affect mostly intravenous drug users and patients who underwent valvular surgery with suboptimal infection control procedures, fungal endocarditis is now mostly observed in patients with severe immunodeficiency (onco-haematology), in association with chronic central venous access and broad-spectrum antibiotic use. The incidence of fungal endocarditis has probably decreased in most developed countries with access to harm-reduction policies (i.e. needle exchange programmes) and with improved infection control procedures during cardiac surgery. Use of specific blood culture bottles for diagnosis of fungal endocarditis has decreased due to optimisation of media and automated culture systems. Meanwhile, the advent of rapid techniques, including fungal antigen detection (galactomannan, mannan/anti-mannan antibodies and β-1,3-d-glucans) and PCR (e.g. universal fungal PCR targeting 18S rRNA genes), shall improve sensitivity and reduce diagnostics delays, although limited data are available on their use for the diagnosis of fungal endocarditis. New antifungal agents available since the early 2000s may represent dramatic improvement for fungal endocarditis: (i) a new class, the echinocandins, has the potential to improve the management of Candida endocarditis owing to its fungicidal effect on yeasts as well as tolerability of increased dosages; and (ii) improved survival in patients with invasive aspergillosis with voriconazole compared with amphotericin B, and this may apply to Aspergillus sp. endocarditis as well, although its prognosis remains dismal. These achievements may allow selected patients to be cured with prolonged medical treatment alone when surgery is considered too risky.</description>
<date>2014-09-30</date>
</dc>
</metadata>
</record>
</GetRecord>
</OAI-PMH>
